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Bupropion  (BUP),  a substituted  phenyl-ethylamine,  has  been  utilized  for  the  treatment  of  depression
and  for  smoking  cessation,  however,  one  concern  is  that  BUP may  increase  a  risk  of psychosis  similar
to  other  substituted  phenyl-ethylamine  amphetamine  (AMPH)  and methamphetamine  (MetAMPH).  BUP
promotes  ambulation  in mice  and  causes  behavioral  sensitization  on the ambulation-promoting  effect
when  repeatedly  administered  as  well  as  AMPH  and  MetAMPH.  The  present  study  aimed  to elucidate  brain
regions  and  monoaminergic  neurotransmitters  that  are  involved  in  the  ambulation-promoting  effect  of
BUP. c-Fos-like  immunoreactivity  (c-Fos-IR)  mapping  in  brain  in  combination  with  measuring  ambulatory
activity  was  conducted  to determine  brain  region(s)  that  is  involved  in  the ambulatory  effect  of  BUP.
Three  kinds of statistical  analyses  for c-Fos-IR  in  24  brain  regions  consistently  showed  that  c-Fos-IR  in  the
Caudate putamen  (CPu)  is positively  correlated  with  the  ambulatory  response  to BUP.  In  addition,  multiple
regression  analysis  indicated  that the  ambulatory  response  is  a function  of  c-Fos-IR  not  only  in  the  CPu
but  also in  the  lateral  septum  nucleus  (LS),  median  raphe  nucleus  (MnR),  lateral  globus  pallidus  (LGP),
medial  globus  pallidus  (MGP),  locus  coeruleus  (LC)  and  ventral  hypothalamic  nucleus  (VMH).  Effects  of
BUP on monoaminergic  neurotransmitters  in  the  CPu  were  examined  using  in vivo  microdialysis  method,
as the pharmacological  experiments  indicated  that monoaminergic  neurotransmitters,  dopamine  (DA)ouse
mbulatory activity
triatum
opamine
-Fos mapping
icrodialysis
in particular,  mediate  the ambulatory  response  to BUP.  Response  of  DA in the CPu to BUP  was parallel  to
the  ambulatory  response,  showing  that  DA  in the  CPu  is  involved  in  the  ambulatory  response  to  BUP.  The
present  study  also  suggests  that  other  brain  regions  such  as the LC,  the  origin  nucleus  of norepinephrine
(NE)  neurons,  and  another  neurotransmitter  NE  may  also  play  some  roles for the  ambulatory  response
to BUP,  however,  further  studies  are  needed  to  elucidate  the roles.
© 2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. Introduction
Bupropion (BUP), a substituted phenyl-ethylamine, was  found
o possess therapeutic beneﬁts as an atypical antidepressant
edication [18], smoking-cessation medication [18] and drug
buse-cessation medication [10,14,46]. Clinical use of BUP for the
reatment of depression and for smoking-cessation was approved
y the Food and Drug Administration (FDA) in the United States.
aily dose of 450 mg  is recommended for the treatment of depres-
ion. The original immediate release formulation of BUP is dosed
hree times daily, followed by introduction of the sustained-release
ormulation that is dosed twice daily and the extended-release for-
ulation that is dosed once daily [29].
∗ Corresponding author.
E-mail address: umechan2@nies.go.jp (T. Umezu).
ttp://dx.doi.org/10.1016/j.toxrep.2016.06.005
214-7500/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Though BUP has been extensively utilized for the treatment of
depression and for smoking cessation, one concern is that BUP
may  increase a risk of psychosis [29]. Several studies report that
BUP may  cause or worsen psychosis [6,21,25,27,62]. BUP inhibits
the dopamine (DA) transporter (DAT) and the norepinephrine
(NE) transporter (NET), and is an antagonist at the neuronal nico-
tinic acetylcholine receptors (nAChRs) [48,50]. The IC50 of BUP for
inhibiting DA uptake is higher than the IC50 values for inhibiting
NE uptake and nAChRs function [16]. This pharmacological prop-
erty also suggests that BUP can have the potential for precipitating
psychosis. However, whether or not BUP increase a risk of psy-
chosis and neuronal mechanisms underlying the potential of BUP
to increase the risk have not been elucidated sufﬁciently [29].
BUP promotes ambulatory activity in mice [54,55,59]. Repeated
administration of BUP to the same mouse augments the
ambulation-promoting effect (behavioral sensitization) [58]. These
ambulatory effects of BUP are similar to those of amphetamine
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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AMPH) and methamphetamine (MetAMPH) [22,30], other sub-
tituted phenyl-ethylamine, that have the potential to produce
sychosis-like mental disorder (amphetamine psychosis) [26].
echanism underlying the locomotion-promoting effect of AMPH
n mice is elucidated well [7,24,36,51,64], whereas mechanisms
nderlying the ambulation-promoting effect of BUP have poorly
een elucidated.
The present study aimed to elucidate brain region(s) and neuro-
ransmitter(s) that are involved in the ambulation-promoting effect
f BUP.
Mapping c-Fos-like immunoreactivity (c-Fos-IR), which indi-
ates neuronal activation, is useful for determining brain regions
hat are activated by CNS acting drugs and involved in speciﬁc
ehaviors [43,66]. BUP increases c-Fos-IR in various rat brain
egions [8], whereas effects of BUP on c-Fos-IR in mouse brain have
ot been studied. The present study conducted c-Fos-IR mapping
n combination with measuring ambulatory activity to determine
ouse brain region(s) that is involved in the ambulatory response
o BUP.
BUP inhibits dopamine (DA) transporter (DAT) and nore-
inephrine (NE) transporter (NET) and enhances the extracellular
A and NE levels in rat brain [11,33]. On the other hand, effects
f BUP on monoaminergic neurotransmitters in mouse brain
ave not been elucidated well. The present study examined
hether or not monoaminergic neurotransmitters mediate the
mbulatory response to BUP using drugs that modulate monoamin-
rgic neurotransmission. Drugs used were -methyl-p-tyrosine
AMPT), reserpine (RES), chlorpromazine (CPZ), ﬂuphenazine (FLU),
CH12679 (SCH), spiperone (SPI), haloperidol (HAL) and pimozide
PIM). AMPT and RES deplete monoaminergic neurotransmitters
n brain [17,41,61]. CPZ, FLU, SCH, SPI, HAL and PIM antagonize
A receptors (DARs) and their afﬁnities for DARs are much higher
han those for NE receptors [13,47]. Then, the present study exam-
ned effects of BUP on monoaminergic neurotransmitters in brain
egion(s) that was identiﬁed by the c-Fos-IR study using in vivo
icrodialysis in order to elucidate relationships between responses
o BUP of monoaminergic neurotransmitters in the brain region(s)
nd of the ambulatory activity.
. Materials and methods
.1. Subjects
Male ICR strain mice (Clea Japan, Tokyo, Japan) aged 7–15 weeks
nd weighing 35–45 g at the start of experiments were used. Mice
ere housed in aluminum cages (three mice/cage) with a stainless-
teel mesh top and paper bedding. Commercial solid food (Clea
apan) and tap water were provided ad libitum. The cages were
laced in a room artiﬁcially illuminated by ﬂuorescent lamps on
 12-h light:12-h dark schedule (light period: 07:00–19:00) and
 room temperature of 25 ± 1 ◦C. All experiments were conducted
uring the light phase.
All experiments were performed in accordance with the guide-
ines of the Ethics Committee for Experimental Animals of the
ational Institute for Environmental Studies, Japan.
.2. Drugs
Bupropion HCl (BUP), chlorpromazine HCl (CPZ), ﬂuphenazine
HCl (FLU), SCH12679 ((R)-(−)-Phenyl−2,3,4,5-tetrahydro-1H-7,8-
imethoxy-3-benzazepine) maleate (SCH) and spiperone (SPI)
Sigma-Aldrich, Tokyo, Japan) were prepared in 0.9% NaCl (Nacalai
esque, Kyoto, Japan) solution (saline). Haloperidol (HAL) (Sigma-
ldrich) was prepared in 0.1% acetic acid (Nacalai Tesque) solution.
imozide (PIM) (Sigma-Aldrich), -methyl-p-tyrosine (AMPT) (ICNReports 3 (2016) 552–562 553
Biomedicals, Solon, OH, USA), and reserpine (RES) (Sigma-Aldrich)
were mixed with a small amount of polyoxyethylene sorbitan
monooleate (Tween 80) (Nacalai Tesque) and diluted in saline.
Doses of BUP, CPZ, FLU, and SCH were expressed as the salt weights.
AMPT was intraperitoneally administered to mice, and other
drugs were subcutaneously administered. The administration vol-
ume  was 1 ml/100 g body weight regardless of the type of drug and
dosage.
2.3. Measurement of mouse ambulatory activity
Ambulatory activity was  measured using an ambulometer
(SAM-10; O’Hara and Co., Tokyo, Japan) [55–59,54,52,53,57]
(Appendix A). Each activity cage (20 cm in diameter) is supported by
a fulcrum in the center of the bottom; the fulcrum tilts according to
movement of the mouse in the activity cage. The tilting movement
of the activity cage activates three micro-switches that surround
the cage. The number of activations of micro-switches during a set
time is recorded, and the result is printed out.
After adapting mice to the activity cages for 30 min, saline,
5 mg/kg or 10 mg/kg of BUP was administered to the mice, followed
by measuring the ambulatory activity for 60 min. Combined admin-
istration of saline or 50 mg/kg AMPT plus saline or 2, 4, or 8 mg/kg
RES was performed on mice at the same time one day before
measuring the ambulatory response to 10 mg/kg BUP. Drugs that
preferentially antagonize DARs were administered after 30 min  of
adaptation, 10 min  later followed by measuring the ambulatory
response to 10 mg/kg BUP.
2.4. Immunocytochemistry for c-Fos
2.4.1. Preparation of brain samples
The following procedures were performed in three separate
experiments on mice given saline (n = 8) or BUP (n = 11). We
obtained seven brain samples from mice given saline and 10 brain
samples from mice given BUP. One brain sample from each of the
animal groups was  excluded because of unsuccessful transcardial
perfusion of ﬁxation.
Individual mice were placed in activity cages, and 30 min  later,
saline was administered, followed by measurement of ambulatory
activity for 60 min. After the measurement, they were returned to
their home cages. This procedure was repeated every day for 3 days
to reduce stress to the mice (acclimation procedure), because stress
induces c-Fos-IR in various brain regions [3,23]. On the 4th day,
individual mice were placed in activity cages. After 30 min  of adap-
tation, saline or 10 mg/kg BUP was  administered, and ambulatory
activity was measured for 60 min. Immediately after the end of
the ambulatory measurements, the mice were deeply anesthetized
with pentobarbital (Nembutal®, Sumitomo Dainippon Pharma Co.,
Ltd., Osaka, Japan) and perfused transcardially with saline contain-
ing heparin (Wako Pure Chemical Ind. Ltd., Osaka, Japan) followed
by Speh’s ﬁxative (4% paraformaldehyde, 0.2% saturated picric acid,
and 0.05% glutaraldehyde in 0.1 M phosphate buffer pH 7.4), which
is a modiﬁcation of Zamboni’s ﬁxative [65]. Brains were removed
and post-ﬁxed in the same ﬁxative overnight at 4 ◦C. They were
soaked in 0.1 M phosphate buffer (pH 7.4) containing 25% sucrose
for cryoprotection until they had completely sunk. Brains were
individually frozen using methyl butane cooled by dry ice and
stored at −80 ◦C.
2.4.2. Immunocytochemistry for c-Fos in brain samples
Coronal sections of brains from the olfactory bulb to themidbrain were cut at a thickness of 50 m using a cryostat.
Immunocytochemistry was  performed on free-ﬂoating sections in
four separate batches. Each batch included samples derived from
mice administered either saline or BUP to ensure that the extent of
5 ology
s
T
i
A
(
a
a
b
B
t
w
d
a
b
s
m
2
e
C
q
t
e
r
0
s
r
t
i
e
(
f
n
l
g
n
n
n
c
n
(
t
f
t
c
S
c
2
a
(
w
(
i
a
m
t
r
e
a54 T. Umezu, Y. Shibata / Toxic
taining was balanced between the two groups. After washing with
ris-buffered saline (TBS, pH 7.4) (Nacalai Tesque), sections were
ncubated for 3 days at 4 ◦C in primary antibody to c-Fos (F7799;
nti-c-Fos rabbit IgG, Sigma-Aldrich; 1:5000) in antibody diluent
TBS containing 0.25% -carrageenan, 1% bovine serum albumin,
nd 0.3% Triton X-100 (all from Sigma-Aldrich)) with 0.1% sodium
zide (Nacalai Tesque). Sections were then washed in TBS and incu-
ated in biotinylated secondary goat anti-rabbit IgG (Vector Labs,
urlingame, CA, USA; 1:500) in antibody diluent for 60 min  at room
emperature. After washing with TBS, sections were incubated
ith ABC complex (ABC Elite kit, Vector Labs; 1:750) in antibody
iluent for 90 min. Staining was visualized by reaction with H2O2
nd diaminobenzidine (Sigma-Aldrich). The reaction was  stopped
y washing sections in TBS. Sections were mounted onto subbed
lides, allowed to air dry, dehydrated, and coverslipped using Per-
ount (Sigma-Aldrich).
.4.3. Quantiﬁcation of c-Fos-IR
Microscopic images of stained sections were captured via a cam-
ra (DFC490, Leica, Germany) interfaced with a personal computer.
aptured images at 100 × magniﬁcation were printed in color for
uantiﬁcation of c-Fos-IR (Appendix B).
Twenty four mouse brain regions were selected by referring
o the previous study that examined the effects of BUP on c-Fos
xpression in various rat brain regions [8], and c-Fos-IR in the brain
egions were quantiﬁed. The numbers of c-Fos-IR nuclei in areas
.11-0.8 mm2 in the 24 brain regions were manually counted. The
izes of the examined area were identical throughout each brain
egion except the dentate gyrus (DG). Because the morphology of
he DG was quite different among each brain, the sizes of the areas
n the DG ranged from 0.11 to 0.27 mm2. The other brain regions
xamined were the anterior olfactory nucleus (AO), orbital cortex
medial, ventral) (MO, VO), primary motor cortex (M1), medial pre-
rontal cortex (mPFC), lateral septum nucleus (LS), claustrum (Cl),
ucleus accumbens (NAcb), olfactory tubercle (Tu), ventral pal-
idum (VP), anterior paraventricular thalamic nucleus (PVA), lateral
lobus pallidus (LGP), caudate putamen (CPu), central amygdaloid
ucleus (CeA), medial globus pallidus (MGP), lateral hypothalamic
ucleus (LH), ventral hypothalamic nucleus (VMH), subthalamic
ucleus (STh), ventral tegmental area (VTA), substantia nigra pars
ompacta (SNC), substantia nigra pars reticulate (SNR), dorsal raphe
ucleus (DR), median raphe nucleus (MnR), and locus coeruleus
LC) (Appendix C). The brain regions were identiﬁed according to
he mouse brain atlas [42].
Counting of c-Fos-IR nuclei in the SNR, CPu, and CeA was  per-
ormed in duplicate, and their correlations were examined in order
o conﬁrm the reliability of our c-Fos-IR quantiﬁcation. Correlation
oefﬁcients were 0.9795, 0.8481, and 0.9606 for the CPu, CeA, and
NR, respectively (Appendix D), showing that the quantiﬁcation of
-Fos-IR was reliable.
.5. Measurement of brain monoaminergic neurotransmitters
nd their metabolites using in vivo microdialysis
Mice were anesthetized using 50 mg/kg pentobarbital
Nembutal®) and ﬁxed in a stereotaxic apparatus equipped
ith a mouse adapter (David Kopf, CA, USA). A dialysis probe
D-I-6-02, cut-off 50,000 Da, Eicom, Kyoto) was stereotaxically
mplanted into the brain region determined to be involved in the
mbulatory response to BUP by the c-Fos study according to the
ouse brain atlas [42] and ﬁxed with dental cement. After surgery,
he animals were individually housed in cages and allowed to
ecover for 2–3 days.
Two to three days after surgery, online measurement of the
xtracellular monoaminergic neurotransmitters, DA, NE, and 5-HT,
nd their metabolites, (3,4-dihydroxy-phenylacetic acid (DOPAC), Reports 3 (2016) 552–562
homovanillic acid (HVA), 3-methoxy-4-hydroxy-phenyl-ethylene
glycol (MHPG), and 5-hydroxyindolacetic acid (5-HIAA)) was per-
formed using in vivo microdialysis coupled with high-performance
liquid chromatography (HPLC). The probe-implanted mouse was
placed in a cage for the microdialysis experiment and allowed to
move freely in the cage. Food and water were available ad libi-
tum throughout the microdialysis measurement. Ringer’s solution
(147 mM Na+, 4 mM K+, and 2.3 mM Ca+, 155.6 mM Cl−) was per-
fused at a rate of 2.0 l/min through the probe using a syringe
pump (ESP-64, Eicom). Each dialysate sample was collected for
25 min  using an auto injector (EAS-2, Eicom) that automatically
injected the dialysate sample into HPLC immediately after the end
of each 25-min collection. After at least four dialysate samples were
collected to establish baseline levels, saline or 10 mg/kg BUP was
administered to the mouse, followed by continuous collection of
six dialysate samples. The lag time from the probe tip to the auto
injector was considered to determine the time point for the admin-
istration. After the end of the microdialysis measurement, eosin
solution was perfused through the probe, the mouse was deeply
anesthetized using pentobarbital (Nembutal®), and the brain was
removed and ﬁxed using 10% formaldehyde neutral buffer solution
(Nacalai Tesque). The placement of the probe was veriﬁed histolog-
ically (Appendix E).
Monoaminergic neurotransmitters and their metabolites in
dialysate samples were analyzed using HPLC (HTEC-500, Eicom).
Each sample was analyzed for 25 min  using HPLC during which all
analytes of interest appeared in a chromatogram. Before starting
the microdialysis experiment for each mouse, HPLC was  calibrated
using authentic standard substances for monoaminergic neuro-
transmitters and their metabolites. The column used was SC-50DS
(Eicom), and the mobile phase (pH 3.5) consisted of 83% 0.1 M acetic
acid-citric acid buffer, 17% methanol (Nacalai Tesque), 190 mg/L
octanesulfonic acid (Nacalai Tesque), and 5 mg/L Na2EDTA (Wako
Pure Chemical Ind. Ltd.). The ﬂow rate of the mobile phase was
0.23 ml/min. Monoaminergic neurotransmitters and their metabo-
lites were detected using an electrochemical detector (ECD-300,
Eicom) that included a graphite electrode (WE-3G, Eicom). The
applied voltage was  +700 mV  against an Ag/AgCl reference elec-
trode. Data were collected from HPLC via an interface (EPC-300,
Eicom) to a personal computer and analyzed using software (Pow-
erChrom, AD instruments Japan, Nagoya).
2.6. Statistical analyses
P < 0.05 was considered statistically signiﬁcant in all statistical
analyses.
2.6.1. Ambulatory activity
To eliminate differences in baseline ambulatory activity, the
ambulatory activity of each mouse was  normalized using the total
activity of the mouse during the 30-min adaptation period before
administration of drugs. Normalized ambulatory activity was ana-
lyzed using the Kruskal-Wallis test followed by the Wilcoxon test,
as data were not distributed normally. In the case of the AMPT/RES
administration experiment, not only normalized but also actual
values of ambulatory activity were analyzed using the Kruskal-
Wallis and Wilcoxon tests to examine the effect of AMPT/RES on
the baseline ambulatory activity.
2.6.2. c-Fos-IR
Three kinds of statistical analyses were conducted to determinebrain region(s) in which c-Fos-IR was involved in the ambulatory
response to BUP.
Differences in numbers of c-Fos-IR nuclei in each brain region
between saline-administered and BUP-administered mice were
T. Umezu, Y. Shibata / Toxicology Reports 3 (2016) 552–562 555
Fig. 1. Effect of bupropion (BUP) on ambulatory activity in ICR mice. The panels show normalized ambulatory activity that was obtained by normalizing actual ambulatory
activity to the total ambulatory activity during the 30-min adaptation period before administration in each mouse. (a) Alterations in normalized ambulatory activity before
and  after subcutaneous administration of saline or 5 or 10 mg/kg BUP. Symbols show median values of normalized ambulatory activity for each 10-min period plotted against
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ahe  midpoint of the measurement period, and vertical lines denote the ﬁrst and th
0  mg/kg BUP. (b) Total normalized ambulatory activity for 60 min  after administra
ith  the saline control. The numbers of animals used were 40–120 (N = 40–120).
ompared using the Wilcoxon test, as data were not distributed
ormally.
Relationships between ambulatory activity and c-Fos-IR in the
wenty four brain regions were analyzed using multiple regres-
ion analysis [60]. Square root transformations of the c-Fos-IR data
nd the ambulatory activity were adopted to normalize the data.
he step-wise method was ﬁrst used to select the brain regions in
hich c-Fos-IR was correlated with ambulatory activity, followed
y multiple regression analysis. The best-ﬁt regression equation
as obtained by the least-squares method. Signiﬁcance of the
etermined multiple regression equation was evaluated using anal-
sis of variance (ANOVA) and R2 (coefﬁcients of determination), and
igniﬁcance of the partial regression coefﬁcients was  tested using
he t-test.
Furthermore, the relationship between ambulatory activity and
-Fos-IR in each of the seven brain regions identiﬁed by the multiple
egression analysis was examined using single regression analysis.
he best-ﬁt regression equation was obtained by the least-squares
ethod. Signiﬁcance of the determined single regression equations
as evaluated by ANOVA and R2.
.6.3. Monoaminergic neurotransmitters and their metabolites
In normal mice, the measured values for monoaminergic neu-
otransmitters and their metabolites just before administering
aline or BUP for each mouse were deﬁned as baseline val-
es, and the measured values before and after administration
ere expressed as ratios to the baseline values. In the AMPT-
nd RES-administered mice, actual amounts of monoaminergicartiles. The arrow indicates the time point for the administration of saline or 5 or
f saline or 5 or 10 mg/kg BUP. Data are shown using a box plot. *P < 0.05 compared
neurotransmitters and their metabolites in dialysates were exam-
ined to elucidate the effects of the pretreatment with AMPT
and RES on their baseline values and responses of them to
BUP.
Measuring 5-HT was  difﬁcult because the retention time was
close to 25 min  in many cases. In addition, as the NE and MHPG
measured in the dialysates in the present study were insensitive
to pretreatment with AMPT and RES, the measured values for NE
and MHPG were believed to be derived from other obstructive
sources. Thus, we  excluded NE, MHPG, and 5-HT from the examina-
tions. Alterations in DA, DOPAC, HVA, and 5-HIAA in normal mice
after administration of saline or BUP were analyzed using two-way
repeated ANOVA followed by the Dunnett test that compared BUP
data with saline data at each time point. Alterations in DA, DOPAC
and HVA after administration of saline or BUP in the mice pretreated
with AMPT/RES or saline were analyzed using three-way repeated
ANOVA followed by two-way ANOVA, one-way ANOVA, and the
Dunnett test.
3. Results
3.1. Effect of BUP on mouse ambulatory activity
When mice were placed into the activity cages, they exhibited
high ambulatory activity, followed by a decrease in activity during
the 30-min adaptation period. After the adaptation period, saline or
5 or 10 mg/kg BUP was administered to the mice. The ambulatory
activity was signiﬁcantly promoted by administration of 10 mg/kg
556 T. Umezu, Y. Shibata / Toxicology Reports 3 (2016) 552–562
Fig. 2. (a) Daily changes in total ambulatory activity for 60 min  after subcutaneous administration of saline or BUP. All mice were given saline on days 1–3 (acclimation
session). On day 4 (challenge session), one group was given saline (N = 7), and another group was given 10 mg/kg BUP (N = 10). Symbols show median values of total normalized
ambulatory activity for 60 min  after administration, and vertical lines denote the ﬁrst and third quartiles. *P < 0.05 BUP vs. saline on day 4 (challenge session). (b) Time course
of  ambulatory activity before and after administration of saline or 10 mg/kg BUP on day 4. The arrow indicates time point for the administration. Immediately after the end of
the  ambulatory measurement, the mice were transcardially perfused with ﬁxative, and their brains were later used for c-Fos immunocytochemistry. Symbols show median
values  of normalized ambulatory activity for each 10-min period. Symbols were plotted against the midpoint of the measurement period. Vertical lines denote the ﬁrst and
third  quartiles. *P < 0.05 BUP vs. saline.
en sal
B
T
t
a
(Fig. 3. c-Fos-IR in the CPu (a) and PVA (b) of mice that were giv
UP (Kruskal-Wallis test; 2 2 = 64.9426, P < 0.0001) (Fig. 1(a), (b)).
he ambulatory activity reached a maximum 15 min  after adminis-
ration of 10 mg/kg BUP, followed by a decrease in the ambulatory
ctivity to the level of the saline-administered mice within 60 min
Fig. 1(a)).ine or10 mg/kg BUP. Data are shown using a box plot. *P < 0.05.
3.2. Effect of BUP on c-Fos-IR in 24 brain regions and the
relationships between ambulatory activity and c-Fos-IR in the
brain regionsThe ambulatory activity on the 4th day (challenge session) was
signiﬁcantly promoted by 10 mg/kg BUP after 3 consecutive days
T. Umezu, Y. Shibata / Toxicology Reports 3 (2016) 552–562 557
Fig. 4. A result of single regression analysis between ambulatory activity and c-Fos-
IR  in the CPu. The best-ﬁt regression line was determined using the least-squares
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Fig. 5. Effect of pretreatment with saline or -methyl-p-tyrosine (AMPT) + reserpine
(RES) on response of ambulatory activity to 10 mg/kg BUP. (a) Changes in actual
ambulatory activity. (b) Changes in normalized ambulatory activity. Symbols show
Fig. 6 illustrates the dose effects of (a) HAL, (b) CPZ, (c) PIM,
(d) FLU, (e) SCH, and (f) SPI on the ambulatory effect of 10 mg/kgethod. Statistics for the regression equation are shown in Table 2.
f acclimation (2 1 = 8.5714, P = 0.0034) (Fig. 2(a), (b)). Immedi-
tely after the ambulatory measurement, the brains of the mice
ere ﬁxed by transcardial perfusion of ﬁxative and used for c-Fos
mmunocytochemistry.
c-Fos-IR nuclei were quantiﬁed in 24 brain regions of the mice
iven saline or BUP. The number of c-Fos-IR nuclei in the CPu of
ice that received BUP was signiﬁcantly larger (Fig. 3(a)), and the
umber of c-Fos-IR nuclei in the PVA was signiﬁcantly smaller
Fig. 3(b)) than those of mice that received saline (CPu; 21 = 4.047,
 = 0.0442, PVA; 21 = 5.4857, P = 0.0192). No signiﬁcant differences
ere observed in the numbers of c-Fos-IR nuclei in other brain
egions between mice given BUP and saline (data not shown).
The relationships between the ambulatory activity and the num-
ers of c-Fos-IR nuclei in the 24 brain regions were examined. Seven
rain regions were selected by the step-wise method, and multiple
egression analysis indicated the following equation:
SQRT(normalized ambulation) = a × SQRT(c-Fos-IRinCPu) + b
× SQRT(c-Fos-IRinLS)  + c × SQRT(c-Fos-IRinMnR) + d
× SQRT(c-Fos-IRinLGP) + e × SQRT(c-Fos-IRinMGP) + f
× SQRT(c-Fos-IRinLC)  + g × SQRT(c-Fos-IRinVMH) + Intercept
here SQRT is square root transformation of the measured value,
nd a, b, c. . ..  . ..  are partial regression coefﬁcients for the variables.
etermined values for the partial regression coefﬁcients and the
esults of statistical tests for them are shown in Table 1. The mul-
iple regression equation was signiﬁcant (ANOVA: F(7, 8) = 7.3737,
 = 0.0057), and R2 was 0.865808.
The relationships between the ambulatory activity and the num-
er of c-Fos-IR nuclei in each of the seven brain regions were
xamined using single regression analysis. The determined regres-
ion equations for each of the seven brain regions and their statistics
re shown in Table 2. The single regression equation for the CPu was
igniﬁcant (Fig. 4).the median values of ambulatory activity for each 10-min period that were plotted
against the midpoint of the measurement period, and vertical lines denote the ﬁrst
and third quartiles. *P < 0.05 compared with saline control. N = 32–36.
3.3. Effect of pretreatment with AMPT and RES on ambulatory
effect of BUP
Pretreatment with 50 mg/kg AMPT and 2–8 mg/kg RES exten-
sively reduced the baseline ambulatory activity (Fig. 5(a)). In
addition, the pretreatment also extensively reduced the effect
of 10 mg/kg BUP on the actual ambulatory activity (Fig. 5(a)).
Response of the normalized ambulatory activity to BUP also signiﬁ-
cantly decreased depending on time and the dose of RES (at 25 min,
23 = 8.4874, P = 0.0369: at 35 min, 23 = 15.0212, P = 0.0018:
at 45 min, 23 = 13.3536, P = 0.0039: at 55 min, 23 = 20.3453,
P = 0.0001) (Fig. 5(b)). Of note, pretreatment with 50 mg/kg AMPT
and 8 mg/kg RES abolished the ambulatory response to BUP.
3.4. Effects of drugs that preferentially antagonize DARs on
response of ambulatory activity to BUPBUP. All drugs consistently attenuated the ambulation-promoting
effect of BUP. (HAL: 24 = 71.982, P < 0.0001; CPZ: 24 = 78.4963,
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Table  1
Statistics for each partial regression coefﬁcient obtained by multiple regression analysis for relationships between the ambulatory activity and c-Fos-IR in seven brain regions.
Explanatory variables Partial regression coefﬁcients Determined value t value Probability
SQRT(c-Fos-IR in the CPu) a 0.6740728 4.6 0.0018
SQRT(c-Fos-IR in the LS) b 0.1291112 0.82 0.4363
SQRT(c-Fos-IR in the MnR) c 0.2988483 2.35 0.0464
SQRT(c-Fos-IR in the LGP) d −0.326261 −1.53 0.1637
SQRT(c-Fos-IR in the MGP) e 0.2327495 2.02 0.0775
SQRT(c-Fos-IR in the LC) f −0.371602 −2.43 0.0414
SQRT(c-Fos-IR in the VMH) g −0.182014 −2.62 0.0307
Intercept 0.333934 0.73 0.486
Abbreviations: SQRT; square transformation of the measured value, c-Fos-IR; c-Fos-like immunoreactivity, CPu; caudate putamen, LS; lateral septum nucleus, MnR; median
raphe  nucleus, LGP; lateral globus pallidus, MGP; medial globus pallidus, LC; locus coeruleus, VMH; ventral hypothalamic nucleus.
Table  2
Statistics of single regression equations for relationships between the ambulatory activity and c-Fos-IR in each of seven brain regions.Single regression equation.
SQRT(normalized ambulation) = (Regression coefﬁcient) × (Explanatory variable) + Intercept.
Explanatory variable Regression coefﬁcient Intercept F value Probability R2
SQRT(c-Fos-IR in the CPu) 0.409049 0.5862859 F(1.15) = 10.6043 0.0053 0.414162
SQRT(c-Fos-IR in the LS) 0.0092656 1.2033837 F(1.15) = 0.0037 0.9525 0.000245
SQRT(c-Fos-IR in the MnR) 0.3405928 0.357357 F(1.15) = 4.1809 0.0588 0.217971
SQRT(c-Fos-IR in the LGP) 0.2623237 0.9954338 F(1.15) = 1.5488 0.2324 0.093589
SQRT(c-Fos-IR in the MGP) 0.2928349 0.9146221 F(1.15) = 4.0894 0.0614 0.214223
SQRT(c-Fos-IR in the LC) 0.0956728 1.007142 F(1.14) = 0.2736 0.6091 0.01917
SQRT(c-Fos-IR in the VMH) −0.036343 1.3765973 F(1.15) = 0.2451 0.6277 0.016079
Abbreviations: SQRT; square transformation of the measured value, c-Fos-IR; c-Fos-like immunoreactivity, CPu; caudate putamen, LS; lateral septum nucleus, MnR; median
raphe  nucleus, LGP; lateral globus pallidus, MGP; medial globus pallidus, LC; locus coeruleus, VMH; ventral hypothalamic nucleus.
F azine
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Pig. 6. Effects of 0.032–0.125 mg/kg haloperidol (HAL) (a), 0.25–1 mg/kg chlorprom
d),  1–10 mg/kg SCH12679 (SCH) (e), and 0.032–0.125 mg/kg spiperone (SPI) (f) o
n  normalized total ambulatory activity for 60 min  after administration. (a) N = 2
aline  + saline. *P < 0.05 compared with saline + BUP.
 < 0.0001; PIM: 24 = 71.7352, P < 0.0001; FLU: 24 = 118.4002,
 < 0.0001; SCH: 24 = 27.9333, P < 0.0001; SPI: 24 = 43.8773,
 < 0.0001). (CPZ) (b), 5–20 mg/kg pimozide (PIM) (c), 0.0625–0.25 mg/kg ﬂuphenazine (FLU)
effect of 10 mg/kg BUP on ambulatory activity. Data are shown using a box plot
N = 20, (c) N = 30–40, (d) N = 30-50, (e) N = 10, (f) N = 18. #P < 0.05 compared with
3.5. Effects of BUP on extracellular DA, DOPAC, HVA, and 5-HIAA
in the CPu
The c-Fos-IR study indicated that the CPu was involved in the
ambulatory response to BUP, and the pharmacological studies
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Fig. 7. Alterations in dopamine (DA), its metabolites DOPAC and HVA, and 5-HIAA,
a  metabolite of serotonin (5-HT), in microdialysis samples obtained from the CPu of
mice before and after administration of saline or 10 mg/kg BUP. The actual measured
values for each compound just before administering saline or BUP in each mouse
were  deﬁned as the baseline values, and all measured values were expressed as
ratios to the baseline values. Symbols denote mean values that were plotted against
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Fig. 8. Comparisons of alterations in ambulatory activity with alterations in DA
levels in dialysates of the CPu before and after administration of saline or 10 mg/kg
BUP. Data are those shown in Fig. 1 and Fig. 7.
Fig. 9. Alterations in actual measured values of DA in dialysates obtained from the
CPu before and after subcutaneous administration of saline or 10 mg/kg BUP. The
mice were pretreated with saline or AMPT + RES. Symbols denote the mean values
that were plotted against the midpoint of the measurement period, and vertical lineshe midpoint of the measurement period, and vertical lines indicate standard error
f the mean (SEM). *P < 0.05 compared with saline. N = 17–20.
uggested that monoaminergic neurotransmitters, DA in particu-
ar, mediated the ambulatory response to BUP. Thus, we examined
ffects of BUP on extracellular monoaminergic neurotransmit-
ers in the CPu using in vivo microdialysis. A dialysis probe was
tereotaxically implanted into the CPu (AP: +0.1 mm,  ML: +2.0 mm,
V: −2.8 mm)  of mice according to the mouse brain atlas [42]
Appendix E).
Fig. 7 illustrates alterations of DA, its metabolites DOPAC and
VA, and 5-HIAA, a metabolite of serotonin (5-HT), in dialysates of
he CPu before and after administration of saline or 10 mg/kg BUP.
he level of DA in the dialysates signiﬁcantly increased and reached
 maximum at 37.5 min  after administration of BUP compared
ith that after saline administration (repeated-measures ANOVA;
ose: F(1, 33) = 119.1605, P < 0.0001; time: F(8, 26) = 18.6742,
 < 0.0001; interaction: F(8, 26) = 23.1516, P < 0.0001). Signiﬁcantly
igher levels of DA persisted until 137.5 min  after BUP admin-
stration. Levels of DOPAC and HVA after BUP administration
igniﬁcantly decreased compared with those after saline admin-
stration (DOPAC: dose: F(1, 34) = 18.726, P = 0.0001; time: F(8,
7) = 11.0811, P < 0.0001; interaction: F(8, 27) = 9.6829, P < 0.0001;
VA; dose: F(1, 34) = 5.5205, P = 0.0247, time: F(8, 27) = 5.4972,
 = 0.0004, interaction: F(8, 27) = 5.4972, P = 0.0004). On the other
and, the level of 5-HIAA did not alter after BUP administration
dose; F(1, 34) = 0.0222, P = 0.8825, time; F(8, 27) = 1.7864, P = 0.124,
nteraction; F(8, 27) = 1.2068, P = 0.3321).
The time course of alteration in ambulatory activity (Fig. 1) was
ompared with that in the extracellular DA in the CPu (Fig. 7) after
dministration of BUP or saline (Fig. 8). The ambulatory activity
ppeared to increase, accompanied by an increase in the extracel-
ular level of DA in the CPu, and the ambulatory activity appeared
o decrease to the control level when the extracellular level of DA
n the CPu decreased, although the level of DA in BUP-administered
ice was signiﬁcantly higher than that of control mice up to
37.5 min  after administration.indicate the standard error of the mean (SEM). *P < 0.05 compared with the saline
pretreated control. N = 6–8.
3.6. Effect of pretreatment with AMPT and RES on response of
extracellular DA in the CPu to BUP
Pretreatment with 50 mg/kg AMPT and 8 mg/kg RES, that
remarkably decreased the baseline ambulatory activity (Fig. 5(a)),
extensively reduced the actual amounts of DA in the dialysates
of the CPu (three-way ANOVA; pretreatment; F(1, 25) = 79.9599,
P < 0.0001; saline or BUP; F(1, 25) = 2.727, P = 0.065; time; F(8,
18) = 2.9876, P = 0.0256) (Fig. 9). The actual amount of DA signif-
icantly increased after administration of 10 mg/kg BUP  in mice
pretreated with saline (two-way ANOVA; saline or BUP; F(1,
12) = 5.3938, P = 0.0386, time; F(8, 5) = 1.8636, P = 0.2554, interac-
tion; F(8, 5) = 1.99, P = 0.2326), whereas the actual amounts of DA
did not show any signiﬁcant alterations after BUP  administration
in mice pretreated with AMPT and RES (two-way ANOVA; saline
or BUP; F(1, 12) = 0.9457, P = 0.35; time; F(8, 5) = 1.324, P = 0.3945,
interaction; F(8, 5) = 0.4796, P = 0.8302). Thus, pretreatment with
50 mg/kg AMPT and 8 mg/kg RES, that abolished the ambulatory
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esponse to BUP (Fig. 5), abolished the response of extracellular DA
n the CPu to BUP.
. Discussion
This is the ﬁrst study that examined c-Fos-IR expression in brain
f mice to which BUP was administered. In the present study, sig-
iﬁcant increase in c-Fos-IR relative to saline was observed only
n the CPu of mice given 10 mg/kg BUP in the activity cage, though
igniﬁcant increase in c-Fos-IR relative to saline is observed in 42 of
4 brain regions including the CPu and PVA in rats given 20 mg/kg
UP in their home cages [8]. These different results could be due
o several factors including differences in experimental conditions,
nimal species, and dose administered. It is known that AMPH
nduces c-Fos-IR in brain in different manners depending on the
xperimental environment [5,39].
Three kinds of analyses for c-Fos-IR (comparison between saline
reated group and BUP administered group, multiple regression
nalysis, single regression analysis) consistently indicated that
-Fos-IR in CPu positively correlated with the ambulatory activ-
ty, showing that neuronal activation in the CPu is involved in
he ambulatory response to BUP. This result could be due to the
haracteristic of the tilting cage method that is more sensitive to
orizontal movement such as locomotion of mouse in the activ-
ty cage. AMPH increases locomotion and c-Fos-IR in the CPu in
ice, and the degree of c-Fos-IR in the CPu is positively corre-
ated with the degree of locomotion promoted by AMPH [66].
t is probable that 10 mg/kg BUP principally increases horizontal
ovement of mouse in the activity cage through activating the
Pu.
Co-administration of AMPT and RES abolished the ambulatory
esponse to BUP. Furthermore, HAL, CPZ, PIM, FLU, SCH, and SPI
educed the ambulatory response to BUP. These pharmacological
tudies indicate that monoaminergic neurotransmitters, DA in par-
icular, mediate the ambulatory response to BUP. Then, the present
tudy examined effects of BUP on monoaminergic neurotransmit-
ers in the CPu, as the c-Fos-IR study showed the CPu is involved
n the ambulatory response to BUP. BUP signiﬁcantly increased
xtracellular DA level in the CPu at the dose that promoted the
mbulatory activity. The ambulatory activity appeared to increase,
ccompanied by an increase in the extracellular level of DA in the
Pu, and the ambulatory activity appeared to decrease to the con-
rol level when the extracellular level of DA in the CPu decreased.
he pretreatment with AMPT and RES, that abolished the ambu-
atory response to BUP, abolished the response of DA in the CPu
o BUP. These ﬁndings show that DA in the CPu is involved in
he ambulation-promoting effect of BUP. DAT is expressed in the
ouse CPu [49], suggesting that BUP increases extracellular level
f DA primarily through inhibiting DAT in the mouse CPu as in the
ase of the rat CPu [33,37,38]. Increase of extracellular level of DA
ust increase c-Fos-IR in the CPu in mice given BUP as DA induces
-Fos-IR through DARs [64,36,15].
The number of c-Fos-IR was signiﬁcantly smaller in the PVA,
owever, c-Fos-IR in the PVA was not correlated with the ambu-
atory response to BUP. The results suggest that BUP affects the
VA functions [4,40] but the PVA is not related to the ambulatory
esponse to BUP. Multiple regression analysis indicated that the
mbulatory activity was a function of c-Fos-IR not only in the CPu
ut also in the LS, MnR, LGP, MGP, LC, and VMH. These brain regions
nteract one another. For example, the LGP and MGP  receive neu-
onal input from the CPu that is known as an indirect pathway from
he CPu to the SNR. The indirect pathway mediates the locomotor
ffect of AMPH in mice [24]. The CPu receives neuronal input from
he LC and MnR  in mice [19,35]. Interactions among these brain
egions may  also be involved in the ambulatory response to BUP. Reports 3 (2016) 552–562
Multiple regression analysis suggests that neuronal activity in
the LC, the origin nucleus of NE neurons, is involved in the ambu-
latory response to BUP. The mouse CPu receives NE input from the
LC and expresses NET [19,45]. BUP inhibits NET [16]. NE induces c-
Fos through NE receptors [9] that are expressed in the CPu of mice
[20]. NE may  also play some roles for the effects of BUP on the neu-
ronal activity in the CPu and the ambulatory activity, however, the
current microdialysis study unfortunately failed to elucidate reli-
able responses to BUP of NE and its metabolite MHPG in the CPu.
The results are probably due to low levels of NE and MHPG in the
mouse CPu and the low IC50 of BUP for inhibiting NET [16]. BUP did
not affect extracellular level of 5-HIAA, a metabolite of serotonin
(5-HT), in the CPu in mice similar to in rats [11,33,37]. As increase
of extracellular DA was  accompanied by decrease of extracellular
HVA and DOPAC in mice given BUP, BUP may  not affect serotonergic
state in the CPu in mice.
Striatal DA system is involved in the locomotion-promoting
effects of AMPH and MetAMPH in mice [7,24,36,51,64], and sen-
sitization to the locomotor effects of AMPH and MetAMPH has
been well studied as animal models of AMP  and/or MetAMPH psy-
chosis [28,44]. On the other hand, the “endogenous sensitization”
hypothesis of schizophrenia has been proposed. The hypothesis
postulates that a sensitized DA system is intrinsic to the disease and
is responsible for the genesis of psychotic symptoms [1,12,32,34].
The hypothesis is supported by the reports that demonstrate
enhanced striatal DA release induced by an acute AMPH chal-
lenge in ﬁrst-episode schizophrenia patients relative to healthy
controls [1,12,32] and overexpression of mesolimbic D2 recep-
tors in the patients [2,31,63]. As BUP produces sensitization to the
ambulation-promoting effect in mice [58] and the present study
revealed that the DA in the CPu is involved in the ambulation-
promoting effect of BUP, the concern about the potential of BUP
to increase a risk of psychosis [29] seems reasonable.
In conclusion, the present study elucidated that DA in the CPu
is involved in the ambulation-promoting effect of BUP in mice. The
results of the present study suggest that other brain regions such
as the LS, MnR, LGP, MGP, LC and VMH  and another neurotrans-
mitter NE also play some roles for the ambulatory response to BUP,
however, elucidating the roles must await further research.
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